FDA clears Varian’s TrueBeam systems for low-dose radiation therapy in osteoarthritis
Varian has received US Food and Drug Administration (FDA) clearance for its TrueBeam radiotherapy systems to use low-dose radiation therapy…
20 Mar 2026
Providence Medical enrols first patients in CORUS-LX system trial
Providence Medical Technology has enrolled the first subjects in its prospective, randomised controlled trial (RCT) assessing the CORUS-LX system to treat degenerative lumbosacral disease. The multi-centre trial will include patients…
20 Mar 2026
LivaNova eyes 2027 launch of neural sleep apnoea therapy after FDA approval
LivaNova’s aura6000 system has obtained premarket approval (PMA) from the US Food and Drug Administration (FDA), charting a course for an anticipated launch of the moderate- to severe obstructive sleep…
20 Mar 2026
Embecta agrees to acquire Owen Mumford
Embecta has signed a definitive agreement to acquire UK-based Owen Mumford Holdings for up to £150m ($172.6m), to enhance its global presence in drug delivery technologies. The agreement includes an…
19 Mar 2026
CISA urges organisations to harden security posture following Stryker cyberattack
The US Cybersecurity and Infrastructure Security Agency (CISA) has issued an alert advising organisations to harden their security posture in light of a recent cyberattack on medical device company Stryker.…
19 Mar 2026
Nia Therapeutics plans FIH memory loss implant trial after FDA green light
Nia Therapeutics’ neurostimulation device for addressing memory loss has secured breakthrough device designation from the US Food and Drug Administration (FDA), paving the way towards the company’s application for an…
18 Mar 2026
JenaValve strikes US market first with approval in TAVR-AR indication
JenaValve’s Trilogy transcatheter aortic valve replacement device for severe aortic regurgitation (TAVR-AR) treatment has obtained pre-market approval (PMA) from the US Food and Drug Administration (FDA), making it the first…